This large-scale cohort study investigates whether gestational selective serotonin reuptake inhibitor (SSRI) treatment impacts newborn thyroid function. Using data from 105,928 mother-infant dyads, the study examines thyroxine (TT4) levels in newborns and potential contributing factors.
Key findings:
SSRI-exposed infants had lower birth weight and higher rates of small-for-gestational-age (SGA) compared to non-exposed infants.
There was no significant difference in newborn thyroid function (TT4 levels) between SSRI-exposed and non-exposed infants.
Maternal factors such as advanced age, IVF conception, and cesarean delivery had greater impacts on thyroid function than SSRI use.
SSRI-treated mothers had higher rates of gestational diabetes, hypertension, and proteinuria.
This study provides reassurance that gestational SSRI use does not directly affect newborn thyroid function, supporting continued SSRI use in pregnancy when clinically necessary.